glp-1 use in type 1 diabetes Drugs and Diabetes: Less Insulin, Better Time Range — What the Evidence Use of Glucagon-Like Peptide-1 |

Safety Considerations and Provider Eligibility Assessment GLP-1 supplements marketed without active peptides carry minimal direct safety risk but may delay appropriate treatment

Consequently, further investigation is warranted [29]

Competitive Landscape and Strategic Positioning The market is early-stage, though it is already attracting nutrition brands, ingredient companies, and clinically adjacent wellness operators

GLP-1 medications typically help patients lose 12-20% of body weight over 6-12 months

A post-hoc subgroup analysis was conducted to investigate trials evaluating semaglutide separately to assess whether individual interventions contributed disproportionately to the overall findings (Supplementary Appendix D)